Docket No. JAB-1694

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants	:	Jean F.A. Lacrampe et al.
Serial No.	:	
Filed	:	
Title	:	INTERLEUKIN-5 INHIBITING 6-AZAURACIL DERIVATIVES
Art Unit	:	
Examiner	:	

Honorable Commissioner of Patents
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Dear Sir:

Prior to examination, please amend the above-identified application as follows:

In the Specification:

Page 1, between the Title and line 4, please insert the following:

-- Cross Reference to Related Applications

This application is a continuation-in-part application of the national stage application filed February 5, 2002, of Application No. PCT/EP00/07358, filed July 31, 2000 which application claims priority from EP 99870170.0, filed August 6, 1999, and EP 99126035.7, filed December 27, 1999. –

In the Claims:

Please amend the claims as follows:

3. (Amended) A compound according to claim 1 having the formula



(I'')

a *N*-oxide, a pharmaceutically acceptable addition salt or a stereochemically isomeric form thereof, wherein :

p represents an integer being 0, 1, 2, 3 or 4;

X represents O, S, NR^5 or a direct bond or-X-R^2 taken together may represent cyano;

Y represents O, S, NR^5, or $S(O)_2$;

each R^1 independently represents C(=0)·Z-R^{14}, C_{1-6}alkyl, halo, polyhaloC_{1-6}alkyl, hydroxy, mercapto, C_{1-6}alkyloxy, C_{1-6}alkylthio, C_{1-6}alkylcarbonyloxy, aryl, cyano, nitro, Het^3, R^6, NR^7R^8 or C_{1-4}alkyl substituted with C(=0)-Z·R^{14}, Het^3, R^6 or NR^7R^8;

R^2 represents Het^1, C_{3-7}cycloalkyl optionally substituted with C(=0)-Z-R^{14}, C_{1-6}alkyl or C_{1-6}alkyl substituted with one or two substituents selected from C(=0)·Z-R^{14}, hydroxy, cyano, amino, mono- or di(C_{1-4}alkyl)amino, C_{1-6}alkyloxy optionally substituted with C(=0)-Z-R^{14}, C_{1-6}alkylsulfonyloxy, C_{3-7}cycloalkyl optionally substituted with C(=0)-Z-R^{14}, aryl, aryloxy, arylthio, Het^1, Het^1oxy and Het^1thio; and if X is O, S or NR^5, then R^2 may also represent aminothiocarbonyl, C_{1-4}alkylcarbonyl optionally substituted with C(=0)-Z-R^{14}, C_{1-4}alkylthiocarbonyl optionally substituted with C(=0)-Z-R^{14} , arylcarbonyl, arylthiocarbonyl, Het^1carbonyl or Het^1thiocarbonyl;

R^3 represents hydrogen, C_{1-6}alkyl or C_{3-7}cycloalkyl;

R^4 represents hydrogen, C_{1-6}alkyl or C_{3-7}cycloalkyl; or

R^3 and R^4 taken together form a C_{2-6}alkanediyl;

R^5 represents hydrogen or C_{1-4}alkyl;

each R^6 independently represents C_{1-6}alkylsulfonyl, aminosulfonyl, piperidinylsulfonyl, mono- or di(C_{1-4}alkyl)aminosulfonyl, mono- or di(benzyl)aminosulfonyl, polyhaloC_{1-6}alkylsulfonyl, C_{1-6}alkylsulfinyl, phenylC_{1-4}alkylsulfonyl, piperazinylsulfonyl, aminopiperidinylsulfonyl, piperidinylaminosulfonyl, *N*-C_{1-4}alkyl-*N*-piperidinylaminosulfonyl or mono-or di(C_{1-4}alkyl)aminoC_{1-4}alkylsulfonyl;

each R^7 and each R^8 are independently selected from hydrogen, C_{1-4}alkyl, hydroxyC_{1-4}alkyl, dihydroxyC_{1-4}alkyl, aryl, arylC_{1-4}alkyl, C_{1-4}alkyloxyC_{1-4}alkyl, C_{1-4}alkylcarbonyl, arylcarbonyl, Het^3carbonyl, mono- or di(C_{1-4}alkyl)aminoC_{1-4}alkyl, arylaminocarbonyl, arylaminothiocarbonyl, Het^3aminocarbonyl, Het^3aminothiocarbonyl, C_{3-7}cycloalkyl, pyridinylC_{1-4}alkyl, C_{1-4}alkanediyl-C(=O)-Z-R^{14}, -C(=O)-Z-R^{14}, -Y-C_{1-4}alkanediyl-C(=O)-Z-R^{14}, Het^3, Het^4 and R^6; or R^7 and R^8 taken together with the nitrogen atom to which they are attached form a radical of formula



R^9 and R^{10} are each independently selected from hydrogen, C_{1-4}alkyl, hydroxyC_{1-4}alkyl, dihydroxyC_{1-4}alkyl, phenyl, phenylC_{1-4}alkyl, C_{1-4}alkyloxyC_{1-4}alkyl, C_{1-4}alkylcarbonyl, phenylcarbonyl, Het^3carbonyl, mono- or di(C_{1-4}alkyl)aminoC_{1-4}alkyl, phenylaminocarbonyl, phenylaminothiocarbonyl, Het^3aminocarbonyl, Het^3aminothiocarbonyl, C_{3-7}cycloalkyl, pyridinylC_{1-4}alkyl, C_{1-4}alkanediyl-C(=O)-Z-R^{14}, -C(=O)-Z-R^{14}, -Y-C_{1-4}alkanediyl-C(=O)-Z-R^{14}, Het^3, Het^4 and R^6; or R^9 and R^{10} taken together with the nitrogen atom to which they are attached form a radical of formula



each R^{11} independently being selected from hydroxy, mercapto, cyano, nitro, halo, trihalomethyl, C_{1-4}alkyloxy optionally substituted with C(=0)-Z-R^{14}, formyl, trihaloC_{1-4}alkylsulfonyloxy, R^6, NR^7R^8, C(=O)$NR^{15}R^{16}$, -C(=O)-Z-R^{14}, -Y-C_{1-4}alkanediyl-C(=O)-Z-R^{14}, aryl, aryloxy, arylcarbonyl, C_{3-7}cycloalkyl optionally substituted with

C(=0)-Z-R^{14}, C_{3-7}cycloalkyloxy optionally substituted with C(=0)-Z-R^{14}, phthalimide-2-yl, Het^3, Het^4 and C(=O)Het^3;

R^{12} and R^{13} are each independently selected from hydrogen, C_{1-4}alkyl, hydroxyC_{1-4}alkyl, dihydroxyC_{1-4}alkyl, phenyl, phenylC_{1-4}alkyl, C_{1-4}alkyloxyC_{1-4}alkyl, C_{1-4}alkylcarbonyl, phenylcarbonyl, mono- or di(C_{1-4}alkyl)aminoC_{1-4}alkyl, phenylaminocarbonyl, phenylaminothiocarbonyl, C_{3-7}cycloalkyl, pyridinylC_{1-4}alkyl, C_{1-4}alkanediyl-C(=O)-Z-R^{14}, -C(=O)-Z-R^{14}, -Y-C_{1-4}alkanediyl-C(=O)-Z-R^{14} and R^6; or R^{12} and R^{13} taken together with the nitrogen atom to which they are attached form a radical of formula



each R^{14} independently represents hydrogen, C_{1-20}acyl (having a straight or branched, saturated or unsaturated hydrocarbon chain having 1 to 20 carbon atoms), C_{1-20}alkyl, C_{3-20}alkenyl optionally substituted with phenyl, C_{3-20}alkynyl, C_{3-7} cycloalkyl, polyhaloC_{1-20}alkyl, Het^5 , phenyl or C_{1-20} alkyl substituted with one or more substituents selected from hydroxy, $NR^{17}R^{18}$, phenyl, mono- or di-(C_{1-4}alkyl)amino, cyano, Het^5 , C_{1-4} alkyloxycarbonyl, phenyl C_{1-4} alkyloxycarbonyl and C_{3-7} cycloalkyl, or R^{14} represents a radical of formula



(a)



(b)



(c)



(d)



(e)



(h)



(i)



(j)



(k)



(l)



(m)



(n)



(o)



(p)



(q)



(r)



(s)



(t)

wherein m is 1 to 4, n is 0 to 5, q is 0 to 2, r is 0 to 2 and s is 0 to 4;

R^a, R^b, R^c, R^d, R^e and R^f are each independently hydrogen, C_{1-6}alkyl, phenyl or C_{3-7}cycloalkyl; or

R^e and R^f taken together may form $-CH_2-CH_2-$, $-CH_2-CH_2-CH_2-$ or $-CH_2-CH_2-CH_2-CH_2-$;

R_g, R_h and R_k are each independently hydrogen or C_{1-4} alkyl;

R_i is C_{1-4}alkyl;

R_j is $-O-R_b$, C_{1-6}alkyl, phenyl or C_{3-7}cycloalkyl optionally substituted with C_{1-4} alkyloxy;

where R_m is hydrogen or C_{1-4} alkyloxy and R_n is hydrogen, C_{1-4}alkyl, C_{3-7}cycloalkyl, phenyl or phenylC_{1-4}alkyl

each Z independently represents O, S, NH, $-CH_2-O-$ or $-CH_2-S-$ whereby $-CH_2-$ is attached to the carbonyl group; or

$-Z-R^{14}$ taken together form a radical of formula



(f)



(g)

R^{15} and R^{16} are each independently selected from hydrogen, C_{1-4}alkyl, hydroxyC_{1-4}alkyl, dihydroxyC_{1-4}alkyl, aryl, arylC_{1-4}alkyl, C_{1-4}alkyloxyC_{1-4}alkyl, -C(=O)-Z-R^{14}, arylcarbonyl, mono- or di(C_{1-4}alkyl)aminoC_{1-4}alkyl, arylaminocarbonyl, arylaminothiocarbonyl, aminocarbonylmethylene, mono- or di(C_{1-4}alkyl) aminocarbonylmethylene, Het^3amino-carbonyl, Het^3aminothiocarbonyl,
pyridinylC_{1-4}alkyl, Het^3 or R^6; or R^{15} and R^{16} taken together with the nitrogen atom to which they are attached form a radical of formula



R^{17} and R^{18} are each independently selected from hydrogen, C_{1-4}alkyl, hydroxyC_{1-4}alkyl, dihydroxyC_{1-4}alkyl, phenyl, phenylC_{1-4}alkyl, C_{1-4}alkyloxyC_{1-4}alkyl, C_{1-4}alkylcarbonyl, phenylcarbonyl, mono- or di(C_{1-4}alkyl)aminoC_{1-4}alkyl, phenylaminocarbonyl, phenylaminothiocarbonyl, C_{3-7}cycloalkyl, pyridinylC_{1-4}alkyl, C_{1-4}alkanediyl-C(=O)-Z-C_{1-6}alkyl, -C(=O)-Z-C_{1-6}alkyl, -Y-C_{1-4}alkanediyl-C(=O)-Z-C_{1-6}alkyl and R^6;

aryl represents phenyl optionally substituted with one, two or three substituents each independently selected from nitro, azido, cyano, halo, hydroxy, C_{1-4}alkyl, C_{3-7}cycloalkyl, C_{1-4}alkyloxy, formyl, polyhaloC_{1-4}alkyl, NR^9R^{10}, C(=O)NR^9R^{10}, C(=O)-Z-R^{14}, R^6, -O-R^6, phenyl, Het^3, C(=O)Het^3 and C_{1-4}alkyl substituted with one or more substituents each independently selected from halo, hydroxy, C_{1-4}alkyloxy, C(=O)-Z-R^{14}, -Y-C_{1-4}alkanediyl-C(=O)-Z-R^{14}, Het^3 or NR^9R^{10};

Het^1 represents a heterocycle selected from pyrrolyl, pyrrolinyl, imidazolyl, imidazolinyl, pyrazolyl, pyrazolinyl, triazolyl, tetrazolyl, furanyl, tetrahydrofuranyl, thienyl, thiolanyl, dioxolanyl, oxazolyl, oxazolinyl, isoxazolyl, thiazolyl, thiazolinyl, isothiazolyl, thiadiazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyranyl, pyridazinyl,

pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, dioxanyl, dithianyl, trithianyl, triazinyl, benzothienyl, isobenzothienyl, benzofuranyl, isobenzofuranyl, benzothiazolyl, benzoxazolyl, benzodioxanyl, indolyl, isoindolyl, indolinyl, purinyl, 1*H*-pyrazolo[3,4-d]pyrimidinyl, benzimidazolyl, quinolyl, isoquinolyl, cinnolinyl, phtalazinyl, quinazolinyl, quinoxalinyl, thiazolopyridinyl, oxazolopyridinyl and imidazo[2,1-b]thiazolyl; wherein said heterocycles each independently may optionally be substituted with one, or where possible, two or three substituents each independently selected from Het^2, R^{11} and C_{1-4}alkyl optionally substituted with one or two substituents independently selected from Het^2 and R^{11};

Het^2 represents a heterocycle selected from pyrrolyl, pyrrolinyl, imidazolyl, imidazolinyl, pyrazolyl, pyrazolinyl, triazolyl, tetrazolyl, furanyl, tetrahydrofuranyl, thienyl, thiolanyl, dioxolanyl, oxazolyl, oxazolinyl, isoxazolyl, thiazolyl, thiazolinyl, isothiazolyl, thiadiazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyranyl, pyridazinyl, dioxanyl, dithianyl, trithianyl, triazinyl, benzothienyl, isobenzothienyl, benzofuranyl, isobenzofuranyl, benzothiazolyl, benzoxazolyl, indolyl, isoindolyl, indolinyl, purinyl, 1*H*-pyrazolo[3,4-d]pyrimidinyl, benzimidazolyl, quinolyl, isoquinolyl, cinnolinyl, phtalazinyl, quinazolinyl, quinoxalinyl, thiazolopyridinyl, oxazolopyridinyl and imidazo[2,1-b]thiazolyl; wherein said heterocycles each independently may optionally be substituted with one, or where possible, two or three substituents each independently selected from Het^4, R^{11} and C_{1-4}alkyl optionally substituted with one or two substituents independently selected from Het^4 and R^{11};

Het^3 represents a monocyclic heterocycle selected from pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl and tetrahydropyranyl; wherein said monocyclic heterocycles each independently may optionally be substituted with, where possible, one, two, three or four substituents each independently selected from hydroxy, C_{1-4}alkyl, C_{1-4}alkyloxy, C_{1-4}alkylcarbonyl, piperidinyl, $NR^{12}R^{13}$, C(=O)-Z-R^{14}, R^6 and C_{1-4}alkyl substituted with one or two substituents independently selected from hydroxy, C_{1-4}alkyloxy, phenyl, C(=O)-Z-R^{14}, -Y-C_{1-4}alkanediyl-C(=O)-Z-R^{14}, R^6 and $NR^{12}R^{13}$;

Het^4 represents a monocyclic heterocycle selected from pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, furanyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyranyl, pyridazinyl and triazinyl;

Het^5 represents a heterocycle selected from pyrrolyl, pyrrolinyl, imidazolyl, imidazolinyl, pyrazolyl, pyrazolinyl, triazolyl, tetrazolyl, furanyl, tetrahydrofuranyl, thienyl, thiolanyl, dioxolanyl, oxazolyl, oxazolinyl, isoxazolyl, thiazolyl, thiazolinyl, isothiazolyl, thiadiazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyranyl, pyridazinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, tetrahydropyranyl, dioxanyl, dithianyl, trithianyl, triazinyl, benzothienyl, isobenzothienyl, benzofuranyl, isobenzofuranyl, benzothiazolyl, benzoxazolyl, benzodioxanyl, indolyl, isoindolyl, indolinyl, purinyl, 1*H*-pyrazolo[3,4-d]pyrimidinyl, benzimidazolyl, quinolyl, isoquinolyl, cinnolinyl, phtalazinyl, quinazolinyl, quinoxalinyl, thiazolopyridinyl, oxazolopyridinyl and imidazo[2,1-b]thiazolyl; wherein said heterocycles each independently may be substituted with, where possible, one, two, three or four substituents each independently selected from hydroxy, C_{1-4}alkyl, C_{1-4}alkyloxy, C_{1-4}alkylcarbonyl, piperidinyl, $NR^{17}R^{18}$, C(=O)-Z-C_{1-6}alkyl, R^6, sulfonamido and C_{1-4}alkyl substituted with one or two substituents independently selected from hydroxy, C_{1-4}alkyloxy, phenyl, C(=O)-Z-C_{1-6}alkyl, -Y-C_{1-4}alkanediyl-C(=O)-Z-C_{1-6}alkyl, R^6 and $NR^{17}R^{18}$;

provided however that

- R^2 is other than C_{1-6} alkyloxycarbonylC_{1-6}alkyl or aminocarbonyl; and
- R^7, R^8, R^9 and R^{10} are other than aminocarbonyl, C_{1-4}alkylcarbonyloxy-C_{1-4}alkylcarbonyl, hydroxy C_{1-4}alkylcarbonyl, C_{1-4}alkyloxycarbonylcarbonyl, C(=O)-O-R^{19}, C_{1-4}alkanediylC(=O)-O-R^{19} or –Y-C_{1-4}alkanediylC(=O)-O-R^{19}; and
- R^{12} and R^{13} are other than C_{1-4}alkylcarbonyloxy-C_{1-4}alkylcarbonyl, hydroxy C_{1-4}alkylcarbonyl or C_{1-4}alkylcarbonylcarbonyl; and
- R^{11} is other than C(=O)-O-R^{19}, Y-C_{1-4}alkanediyl – C(=O)-OR^{19}, $C(=O)NH_2$, $C(=O)NHC_{1-4}$alkyl or $C(=O)NHC_{3-7}$cycloalkyl; and
- R^{15} and R^{16} are other than aminocarbonyl, C_{1-4}alkylcarbonyloxy-C_{1-4}alkylcarbonyl, hydroxy C_{1-4}alkylcarbonyl or C_{1-4}alkyloxycarbonylcarbonyl; and
- aryl is other than phenyl substituted with C(=O)-O-R^{19}, $C(=O)NH_2$, $C(=O)NHC_{1-4}$alkyl, $C(=O)NHC_{3-7}$cycloalkyl and/or with C_{1-4}alkyl substituted with C(=O)-O-R^{19} or Y-C_{1-4}alkanediyl – C(=O)-O-R^{14}; and
- Het^3 is other than a monocyclic heterocycle substituted with C(=O)·O-R^{19} and/or with C_{1-4}alkyl substituted with C(=O)-O-R^{19} and/or Y-C_{1-4}alkanediyl – (=O)-O-R^{19}; and

- in each of the above proviso's R^{19} is defined as hydrogen, C_{1-4}alkyl, C_{3-7}cycloalkyl, aminocarbonylmethylene or mono- or di(C_{1-4}alkyl)aminocarbonylmethylene; and
- the said compound of formula (I) contains at least one – C(=O)-Z-R^{14} moiety.

4. (Amended) A compound according to claim 1 wherein the 6-azauracil moiety is in the para position relative to the carbon atom bearing the -X-R^2, R^3 and R^4 substituents.

5. (Amended) A compound according to claim 1 wherein R^2 is a monocyclic heterocycle selected from pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, furanyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyranyl, pyridazinyl and triazinyl, wherein said monocyclic heterocycles each independently may optionally be substituted with one, or where possible, two or three substituents each independently selected from Het^2, R^{11} and C_{1-4}alkyl optionally substituted with Het^2 or R^{11}.

6. (Amended) A compound according to claim 1 wherein R^3 and R^4 are both methyl and -X-R^2 is Het^1.

7. (Amended) A compound according to claim1 wherein p is 1 or 2 and each R^1 is chloro.

8. (Amended) A compound according to claim 1 wherein R^3 and R^4 are both methyl, -X-R^2 is optionally substituted 2-thiazolyl or 3-oxadiazolyl, the 6-azauracil moiety is in the para position relative to the carbon atom bearing the -X-R^2, R^3 and R^4 substituents, and p is 2 whereby both R^1 substituents are chloro positioned ortho relative to the carbon atom bearing the -X-R^2, R^3 and R^4 substituents.

11. (Amended) A composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of a compound according to claim 1.

Please cancel claims 12 and 13.

14. (Amended) A method for treating eosinophil-dependent inflammatory diseases comprising administering to a subject in need thereof an effective amount of a compound of claim 1.

17. (Amended) A process of imaging an organ, comprising, administering a sufficient amount of a radiolabelled compound of formula (I) as claimed in claim 1 in an appropriate composition, and detecting the emissions from the radioactive compound.

Please cancel claims 19 and 20.

REMARKS/ARGUMENTS

Consideration of the captioned application in view of the foregoing amendments and following remarks is requested.

By this Amendment, claims 12, 13, 19 and 20 were canceled. Accordingly, the pending claims are 1-11, and 14-18.

The specification has been amended to refer to the priority applications.

Enclosed herewith is an Information Disclosure Statement with a copy of the International Search Report and documents cited therein.

Early favorable action on the merits is respectfully requested.

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page(s) is/are captioned "Version with markings to show changes made".

Applicant respectfully requests that a timely Notice of Allowance be issued in this case.

Respectfully submitted,

By: _____
Ellen Ciambrone Coletti
Reg. No. 34,140

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
(732) 524-2359
Dated: February 14, 2002

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the Specification:

Page 1, between the Title and line 4, please insert the following:

-- Cross Reference to Related Applications

This application is a continuation-in-part application of the national stage application filed February 5, 2002, of Application No. PCT/EP00/07358, filed July 31, 2000 which application claims priority from EP 99870170.0, filed August 6, 1999, and EP 99126035.7, filed December 27, 1999. –

In the Claims:

3. (Amended) A compound according to claim[s] 1 [or 2] having the formula



(I'')

a *N*-oxide, a pharmaceutically acceptable addition salt or a stereochemically isomeric form thereof, wherein :

p represents an integer being 0, 1, 2, 3 or 4;

X represents O, S, NR^5 or a direct bond or-X-R^2 taken together may represent cyano;

Y represents O, S, NR^5, or $S(O)_2$;

each R^1 independently represents C(=0)·Z-R^{14}, C_{1-6}alkyl, halo, polyhaloC_{1-6}alkyl, hydroxy, mercapto, C_{1-6}alkyloxy, C_{1-6}alkylthio, C_{1-6}alkylcarbonyloxy, aryl, cyano, nitro, Het^3, R^6, NR^7R^8 or C_{1-4}alkyl substituted with C(=0)-Z·R^{14}, Het^3, R^6 or NR^7R^8;

R^2 represents Het^1, C_{3-7}cycloalkyl optionally substituted with C(=0)-Z-R^{14}, C_{1-6}alkyl or C_{1-6}alkyl substituted with one or two substituents selected from C(=0)·Z-R^{14}, hydroxy,

cyano, amino, mono- or di(C_{1-4}alkyl)amino, C_{1-6}alkyloxy optionally substituted with C(=0)-Z-R^{14}, C_{1-6}alkylsulfonyloxy, C_{3-7}cycloalkyl optionally substituted with C(=0)-Z-R^{14}, aryl, aryloxy, arylthio, Het^1, Het^1oxy and Het^1thio; and if X is O, S or NR^5, then R^2 may also represent aminothiocarbonyl, C_{1-4}alkylcarbonyl optionally substituted with C(=0)-Z-R^{14}, C_{1-4}alkylthiocarbonyl optionally substituted with C(=0)-Z-R^{14} , arylcarbonyl, arylthiocarbonyl, Het^1carbonyl or Het^1thiocarbonyl;

R^3 represents hydrogen, C_{1-6}alkyl or C_{3-7}cycloalkyl;

R^4 represents hydrogen, C_{1-6}alkyl or C_{3-7}cycloalkyl; or

R^3 and R^4 taken together form a C_{2-6}alkanediyl;

R^5 represents hydrogen or C_{1-4}alkyl;

each R^6 independently represents C_{1-6}alkylsulfonyl, aminosulfonyl, piperidinylsulfonyl, mono- or di(C_{1-4}alkyl)aminosulfonyl, mono- or di(benzyl)aminosulfonyl, polyhaloC_{1-6}alkylsulfonyl, C_{1-6}alkylsulfinyl, phenylC_{1-4}alkylsulfonyl, piperazinylsulfonyl, aminopiperidinylsulfonyl, piperidinylaminosulfonyl, *N*-C_{1-4}alkyl-*N*-piperidinylaminosulfonyl or mono-or di(C_{1-4}alkyl)aminoC_{1-4}alkylsulfonyl;

each R^7 and each R^8 are independently selected from hydrogen, C_{1-4}alkyl, hydroxyC_{1-4}alkyl, dihydroxyC_{1-4}alkyl, aryl, arylC_{1-4}alkyl, C_{1-4}alkyloxyC_{1-4}alkyl, C_{1-4}alkylcarbonyl, arylcarbonyl, Het^3carbonyl, mono- or di(C_{1-4}alkyl)aminoC_{1-4}alkyl, arylaminocarbonyl, arylaminothiocarbonyl, Het^3aminocarbonyl, Het^3aminothiocarbonyl, C_{3-7}cycloalkyl, pyridinylC_{1-4}alkyl, C_{1-4}alkanediyl-C(=O)-Z-R^{14}, -C(=O)-Z-R^{14}, -Y-C_{1-4}alkanediyl-C(=O)-Z-R^{14}, Het^3, Het^4 and R^6; or R^7 and R^8 taken together with the nitrogen atom to which they are attached form a radical of formula



R^9 and R^{10} are each independently selected from hydrogen, C_{1-4}alkyl, hydroxyC_{1-4}alkyl, dihydroxyC_{1-4}alkyl, phenyl, phenylC_{1-4}alkyl, C_{1-4}alkyloxyC_{1-4}alkyl, C_{1-4}alkylcarbonyl,

phenylcarbonyl, Het^3carbonyl, mono- or di(C_{1-4}alkyl)aminoC_{1-4}alkyl, phenylaminocarbonyl, phenylaminothiocarbonyl, Het^3aminocarbonyl, Het^3aminothiocarbonyl, C_{3-7}cycloalkyl, pyridinylC_{1-4}alkyl, C_{1-4}alkanediyl-C(=O)-Z-R^{14}, -C(=O)-Z-R^{14}, -Y-C_{1-4}alkanediyl-C(=O)-Z-R^{14}, Het^3, Het^4 and R^6; or R^9 and R^{10} taken together with the nitrogen atom to which they are attached form a radical of formula



each R^{11} independently being selected from hydroxy, mercapto, cyano, nitro, halo, trihalomethyl, C_{1-4}alkyloxy optionally substituted with C(=0)-Z-R^{14}, formyl, trihaloC_{1-4}alkylsulfonyloxy, R^6, NR^7R^8, $C(=O)NR^{15}R^{16}$, -C(=O)-Z-R^{14}, -Y-C_{1-4}alkanediyl-C(=O)-Z-R^{14}, aryl, aryloxy, arylcarbonyl, C_{3-7}cycloalkyl optionally substituted with C(=0)-Z-R^{14}, C_{3-7}cycloalkyloxy optionally substituted with C(=0)-Z-R^{14}, phthalimide-2-yl, Het^3, Het^4 and $C(=O)Het^3$;

R^{12} and R^{13} are each independently selected from hydrogen, C_{1-4}alkyl, hydroxyC_{1-4}alkyl, dihydroxyC_{1-4}alkyl, phenyl, phenylC_{1-4}alkyl, C_{1-4}alkyloxyC_{1-4}alkyl, C_{1-4}alkylcarbonyl, phenylcarbonyl, mono- or di(C_{1-4}alkyl)aminoC_{1-4}alkyl, phenylaminocarbonyl, phenylaminothiocarbonyl, C_{3-7}cycloalkyl, pyridinylC_{1-4}alkyl, C_{1-4}alkanediyl-C(=O)-Z-R^{14}, -C(=O)-Z-R^{14}, -Y-C_{1-4}alkanediyl-C(=O)-Z-R^{14} and R^6; or R^{12} and R^{13} taken together with the nitrogen atom to which they are attached form a radical of formula



each R^{14} independently represents hydrogen, C_{1-20}acyl (having a straight or branched, saturated or unsaturated hydrocarbon chain having 1 to 20 carbon atoms), C_{1-20}alkyl,

C_{3-20}alkenyl optionally substituted with phenyl, C_{3-20}alkynyl, C_{3-7} cycloalkyl, polyhaloC_{1-20}alkyl, Het^5, phenyl or C_{1-20} alkyl substituted with one or more substituents selected from hydroxy, $NR^{17}R^{18}$, phenyl, mono- or di-(C_{1-4}alkyl)amino, cyano, Het^5, C_{1-4} alkyloxycarbonyl, phenyl C_{1-4} alkyloxycarbonyl and C_{3-7} cycloalkyl, or R^{14} represents a radical of formula



(a)



(b)



(c)



(d)



(e)



(h)



(i)



(j)



(k)



(l)



(m)



(n)



(o)



(p)



(q)



(r)



(s)



(t)

wherein m is 1 to 4, n is 0 to 5, q is 0 to 2, r is 0 to 2 and s is 0 to 4;

R^a, R^b, R^c, R^d, R^e and R^f are each independently hydrogen, C_{1-6}alkyl, phenyl or C_{3-7}cycloalkyl; or

R^e and R^f taken together may form $-CH_2-CH_2-$, $-CH_2-CH_2-CH_2-$ or $-CH_2-CH_2-CH_2-CH_2-$;

R_g, R_h and R_k are each independently hydrogen or C_{1-4} alkyl;

R_i is C_{1-4}alkyl;

R_j is $-O-R_b$, C_{1-6}alkyl, phenyl or C_{3-7}cycloalkyl optionally substituted with C_{1-4} alkyloxy;

where R_m is hydrogen or C_{1-4} alkyloxy and R_n is hydrogen, C_{1-4}alkyl,

C_{3-7}cycloalkyl, phenyl or phenylC_{1-4}alkyl

each Z independently represents O, S, NH, $-CH_2-O-$ or $-CH_2-S-$ whereby $-CH_2-$ is attached to the carbonyl group; or

$-Z-R^{14}$ taken together form a radical of formula



(f)



(g)

R^{15} and R^{16} are each independently selected from hydrogen, C_{1-4}alkyl, hydroxyC_{1-4}alkyl, dihydroxyC_{1-4}alkyl, aryl, arylC_{1-4}alkyl, C_{1-4}alkyloxyC_{1-4}alkyl, -C(=O)-Z-R^{14}, arylcarbonyl, mono- or di(C_{1-4}alkyl)aminoC_{1-4}alkyl, arylaminocarbonyl, arylaminothiocarbonyl, aminocarbonylmethylene, mono- or di(C_{1-4}alkyl) aminocarbonylmethylene, Het^3amino-carbonyl, Het^3aminothiocarbonyl,
pyridinylC_{1-4}alkyl, Het^3 or R^6; or R^{15} and R^{16} taken together with the nitrogen atom to which they are attached form a radical of formula



R^{17} and R^{18} are each independently selected from hydrogen, C_{1-4}alkyl, hydroxyC_{1-4}alkyl, dihydroxyC_{1-4}alkyl, phenyl, phenylC_{1-4}alkyl, C_{1-4}alkyloxyC_{1-4}alkyl, C_{1-4}alkylcarbonyl, phenylcarbonyl, mono- or di(C_{1-4}alkyl)aminoC_{1-4}alkyl, phenylaminocarbonyl, phenylaminothiocarbonyl, C_{3-7}cycloalkyl, pyridinylC_{1-4}alkyl, C_{1-4}alkanediyl-C(=O)-Z-C_{1-6}alkyl, -C(=O)-Z-C_{1-6}alkyl, -Y-C_{1-4}alkanediyl-C(=O)-Z-C_{1-6}alkyl and R^6;

aryl represents phenyl optionally substituted with one, two or three substituents each independently selected from nitro, azido, cyano, halo, hydroxy, C_{1-4}alkyl, C_{3-7}cycloalkyl, C_{1-4}alkyloxy, formyl, polyhaloC_{1-4}alkyl, NR^9R^{10}, C(=O)NR^9R^{10}, C(=O)-Z-R^{14}, R^6, -O-R^6, phenyl, Het^3, C(=O)Het^3 and C_{1-4}alkyl substituted with one or more substituents each independently selected from halo, hydroxy, C_{1-4}alkyloxy, C(=O)-Z-R^{14}, -Y-C_{1-4}alkanediyl-C(=O)-Z-R^{14}, Het^3 or NR^9R^{10};

Het^1 represents a heterocycle selected from pyrrolyl, pyrrolinyl, imidazolyl, imidazolinyl, pyrazolyl, pyrazolinyl, triazolyl, tetrazolyl, furanyl, tetrahydrofuranyl, thienyl, thiolanyl, dioxolanyl, oxazolyl, oxazolinyl, isoxazolyl, thiazolyl, thiazolinyl, isothiazolyl, thiadiazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyranyl, pyridazinyl,

pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, dioxanyl, dithianyl, trithianyl, triazinyl, benzothienyl, isobenzothienyl, benzofuranyl, isobenzofuranyl, benzothiazolyl, benzoxazolyl, benzodioxanyl, indolyl, isoindolyl, indolinyl, purinyl, 1*H*-pyrazolo[3,4-d]pyrimidinyl, benzimidazolyl, quinolyl, isoquinolyl, cinnolinyl, phtalazinyl, quinazolinyl, quinoxalinyl, thiazolopyridinyl, oxazolopyridinyl and imidazo[2,1-b]thiazolyl; wherein said heterocycles each independently may optionally be substituted with one, or where possible, two or three substituents each independently selected from Het^2, R^{11} and C_{1-4}alkyl optionally substituted with one or two substituents independently selected from Het^2 and R^{11};

Het^2 represents a heterocycle selected from pyrrolyl, pyrrolinyl, imidazolyl, imidazolinyl, pyrazolyl, pyrazolinyl, triazolyl, tetrazolyl, furanyl, tetrahydrofuranyl, thienyl, thiolanyl, dioxolanyl, oxazolyl, oxazolinyl, isoxazolyl, thiazolyl, thiazolinyl, isothiazolyl, thiadiazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyranyl, pyridazinyl, dioxanyl, dithianyl, trithianyl, triazinyl, benzothienyl, isobenzothienyl, benzofuranyl, isobenzofuranyl, benzothiazolyl, benzoxazolyl, indolyl, isoindolyl, indolinyl, purinyl, 1*H*-pyrazolo[3,4-d]pyrimidinyl, benzimidazolyl, quinolyl, isoquinolyl, cinnolinyl, phtalazinyl, quinazolinyl, quinoxalinyl, thiazolopyridinyl, oxazolopyridinyl and imidazo[2,1-b]thiazolyl; wherein said heterocycles each independently may optionally be substituted with one, or where possible, two or three substituents each independently selected from Het^4, R^{11} and C_{1-4}alkyl optionally substituted with one or two substituents independently selected from Het^4 and R^{11};

Het^3 represents a monocyclic heterocycle selected from pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl and tetrahydropyranyl; wherein said monocyclic heterocycles each independently may optionally be substituted with, where possible, one, two, three or four substituents each independently selected from hydroxy, C_{1-4}alkyl, C_{1-4}alkyloxy, C_{1-4}alkylcarbonyl, piperidinyl, $NR^{12}R^{13}$, C(=O)-Z-R^{14}, R^6 and C_{1-4}alkyl substituted with one or two substituents independently selected from hydroxy, C_{1-4}alkyloxy, phenyl, C(=O)-Z-R^{14}, -Y-C_{1-4}alkanediyl-C(=O)-Z-R^{14}, R^6 and $NR^{12}R^{13}$;

Het^4 represents a monocyclic heterocycle selected from pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, furanyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyranyl, pyridazinyl and triazinyl;

Het[5] represents a heterocycle selected from pyrrolyl, pyrrolinyl, imidazolyl, imidazolinyl, pyrazolyl, pyrazolinyl, triazolyl, tetrazolyl, furanyl, tetrahydrofuranyl, thienyl, thiolanyl, dioxolanyl, oxazolyl, oxazolinyl, isoxazolyl, thiazolyl, thiazolinyl, isothiazolyl, thiadiazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyranyl, pyridazinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, tetrahydropyranyl, dioxanyl, dithianyl, trithianyl, triazinyl, benzothienyl, isobenzothienyl, benzofuranyl, isobenzofuranyl, benzothiazolyl, benzoxazolyl, benzodioxanyl, indolyl, isoindolyl, indolinyl, purinyl, 1*H*-pyrazolo[3,4-d]pyrimidinyl, benzimidazolyl, quinolyl, isoquinolyl, cinnolinyl, phtalazinyl, quinazolinyl, quinoxalinyl, thiazolopyridinyl, oxazolopyridinyl and imidazo[2,1-b]thiazolyl; wherein said heterocycles each independently may be substituted with, where possible, one, two, three or four substituents each independently selected from hydroxy, C_{1-4}alkyl, C_{1-4}alkyloxy, C_{1-4}alkylcarbonyl, piperidinyl, $NR^{17}R^{18}$, C(=O)-Z-C_{1-6}alkyl, R^6, sulfonamido and C_{1-4}alkyl substituted with one or two substituents independently selected from hydroxy, C_{1-4}alkyloxy, phenyl, C(=O)-Z-C_{1-6}alkyl, -Y-C_{1-4}alkanediyl-C(=O)-Z-C_{1-6}alkyl, R^6 and $NR^{17}R^{18}$;

provided however that

- R^2 is other than C_{1-6} alkyloxycarbonylC_{1-6}alkyl or aminocarbonyl; and
- R^7, R^8, R^9 and R^{10} are other than aminocarbonyl, C_{1-4}alkylcarbonyloxy-C_{1-4}alkylcarbonyl, hydroxy C_{1-4}alkylcarbonyl, C_{1-4}alkyloxycarbonylcarbonyl, C(=O)-O-R^{19}, C_{1-4}alkanediylC(=O)-O-R^{19} or –Y-C_{1-4}alkanediylC(=O)-O-R^{19}; and
- R^{12} and R^{13} are other than C_{1-4}alkylcarbonyloxy-C_{1-4}alkylcarbonyl, hydroxy C_{1-4}alkylcarbonyl or C_{1-4}alkylcarbonylcarbonyl; and
- R^{11} is other than C(=O)-O-R^{19}, Y-C_{1-4}alkanediyl – C(=O)-OR^{19}, C(=O)NH_2, C(=O)NHC_{1-4}alkyl or C(=O)NHC_{3-7}cycloalkyl; and
- R^{15} and R^{16} are other than aminocarbonyl, C_{1-4}alkylcarbonyloxy-C_{1-4}alkylcarbonyl, hydroxy C_{1-4}alkylcarbonyl or C_{1-4}alkyloxycarbonylcarbonyl; and
- aryl is other than phenyl substituted with C(=O)-O-R^{19}, C(=O)NH_2, C(=O)NHC_{1-4}alkyl, C(=O)NHC_{3-7}cycloalkyl and/or with C_{1-4}alkyl substituted with C(=O)-O-R^{19} or Y-C_{1-4}alkanediyl – C(=O)-O-R^{14}; and
- Het[3] is other than a monocyclic heterocycle substituted with C(=O)·O-R^{19} and/or with C_{1-4}alkyl substituted with C(=O)-O-R^{19} and/or Y-C_{1-4}alkanediyl – (=O)-O-R^{19}; and

- in each of the above proviso's R^{19} is defined as hydrogen, C_{1-4}alkyl, C_{3-7}cycloalkyl, aminocarbonylmethylene or mono- or di(C_{1-4}alkyl)aminocarbonylmethylene; and
- the said compound of formula (I) contains at least one – C(=O)-Z-R^{14} moiety.

4. (Amended) A compound according to [any of] claim[s] 1 [to 3] wherein the 6-azauracil moiety is in the para position relative to the carbon atom bearing the -X-R^2, R^3 and R^4 substituents.

5. (Amended) A compound according to [any of] claim[s] 1 [to 4] wherein R^2 is a monocyclic heterocycle selected from pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, furanyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyranyl, pyridazinyl and triazinyl, wherein said monocyclic heterocycles each independently may optionally be substituted with one, or where possible, two or three substituents each independently selected from Het^2, R^{11} and C_{1-4}alkyl optionally substituted with Het^2 or R^{11}.

6. (Amended) A compound according to [any of] claim[s] 1 [to 5] wherein R^3 and R^4 are both methyl and -X-R^2 is Het^1.

7. (Amended) A compound according to [any of] claim[s]1 [to 6] wherein p is 1 or 2 and each R^1 is chloro.

8. (Amended) A compound according to [any of] claim[s] 1 [to 7] wherein R^3 and R^4 are both methyl, -X-R^2 is optionally substituted 2-thiazolyl or 3-oxadiazolyl, the 6-azauracil moiety is in the para position relative to the carbon atom bearing the -X-R^2, R^3 and R^4 substituents, and p is 2 whereby both R^1 substituents are chloro positioned ortho relative to the carbon atom bearing the -X-R^2, R^3 and R^4 substituents.

11. (Amended) A composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of a compound according to [any of] claim[s] 1 [to 10].

Please cancel claims 12 and 13.

14. (Amended) [Use of a compound according to any of claims 1 to 10 in the manufacture of a medicament] A method for treating eosinophil-dependent inflammatory diseases comprising administering to a subject in need thereof an effective amount of a compound of claim 1.

17. (Amended) A process of imaging an organ, [characterized by] comprising, administering a sufficient amount of a radiolabelled compound of formula (I) as claimed in claim 1 in an appropriate composition, and detecting the emissions from the radioactive compound.

Please cancel claims 19 and 20.